Mike Dennis

accessibility text

Name

Mike Dennis

Job title

Consultant Haematologist

Email Address

Tracy.Blinkhorn@nhs.net

Qualifications

MB ChB, MRCP, FRCPath, MD

Specialities

Haematology, Myeloma, Stem cell transplantation

Responsibilities

  • Member of the UK AML research network

  • Member of British Society for Haematology

  • Member of the European Haematology Association

  • Member of the American Society of Haematology

  • Member of the European group for Blood and Marrow Transplantation

Professional biography

Professor Mike Dennis qualified in Medicine from the University of Dundee in 1991, completed his physician's training in Liverpool before undertaking his first haematology post in Perth, Australia. He returned to the UK and his first appointment at The Christie in 1996 and then completed his haematology training, including a MD from the University of Liverpool. He was appointed consultant haematologist at The Christie in 2004. Since then, he has been Clinical Director for the Haematology and Transplant unit (2004 to 2014) and Haematological Cancer Pathway Director for Manchester Cancer (2014 to2017). Throughout, he has been clinical lead for acute myeloid leukaemia (AML).

In 2024, Professor Dennis was awarded a Manchester Academic Health Science Centre Clinical Chair by The University of Manchester's Faculty of Biology, Medicine and Health Promotions Committee for a major contribution to haematology research.

Professor Dennis's clinical practice involves the management of patients with all myeloid disease which may require chemotherapy, trials and transplantation.

He is an established expert in AML, a committee member of the UK AML research network, where his roles include Chief investigator (Li1) and Co-chief investigator (AML 19) the premier front line UK trials in AML.

Professor Dennis frequently performs as clinical expert for NICE technology appraisals in AML and is a regular invited speaker on AML nationally and internationally.

Getting the best possible outcome for patients is his primary focus.

His research is in clinical trial development for optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance.

Publications

The Christie Private Care

Professor Dennis also practises privately at The Christie Private Care